Imaging of adenosine A1 receptors in the human brain by positron emission tomography with [11C]MPDX

Ann Nucl Med. 2003 Sep;17(6):511-5. doi: 10.1007/BF03006445.

Abstract

We report the first clinical PET study using [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine ([11C]MPDX) for imaging adenosine A1 receptors in the human brain. The binding of [11C]MPDX evaluated quantitatively as the distribution volume by a graphical analysis was high in the striatum and thalamus, and low in the cerebellum. The distribution pattern of [11C]MPDX was coincident with that of adenosine A1 receptors in vitro reported previously, and was different from those of blood flow and [18F]FDG. The [11C]MPDX PET has the potential for mapping adenosine A1 receptors in the human brain.

Publication types

  • Clinical Trial
  • Validation Study

MeSH terms

  • Brain / diagnostic imaging*
  • Brain / metabolism*
  • Brain Mapping / methods
  • Humans
  • Image Interpretation, Computer-Assisted
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Radiopharmaceuticals / pharmacokinetics
  • Receptor, Adenosine A1 / metabolism*
  • Tissue Distribution
  • Tomography, Emission-Computed / methods*
  • Xanthines / pharmacokinetics*

Substances

  • 1-methyl-8-dicyclopropylmethyl-1-methyl-3-propylxanthine
  • Radiopharmaceuticals
  • Receptor, Adenosine A1
  • Xanthines